Esmelda Montalbán

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Beatriz Grinsztejn, Michael D. Hughes, Justin Ritz et al. · The Lancet HIV · 2019 · 38 citations · Full text

Public Health, Health Sciences, Pharmacotherapy +12

The isolation of Balamuthia mandrillaris from environmental sources from Peru

Alfonso Martín Cabello‐Vílchez, María Reyes-Batllé, Esmelda Montalbán et al. · Parasitology Research · 2014 · 35 citations

Life Sciences, Biology, Botany +6

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

Anchalee Avihingsanon, Michael D. Hughes, Robert A. Salata et al. · Journal of the International AIDS Society · 2022 · 13 citations · Full text

Life Sciences, Pharmacotherapy, Clinical Pharmacology +16

Acute retroviral syndrome is associated with lower CD4+ T cell nadir and delayed viral suppression, which are blunted by immediate antiretroviral therapy initiation

Rose Gabert, Javier R. Lama, Rogelio Valdez et al. · AIDS · 2023 · 10 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17